Результаты поиска

Oncology biosimilars: New developments and future directions.

Biologicals have become an integral part of cancer treatment both as therapeutic agents and as supportive care agents. It is important to know that biologics are large, complex molecular entities requiring extensive immunogenicity testing and pharmacovigilance strategies to ensure no immune response is evoked in the body. Oncology's pharmacological market is dominated by biologics; however, their high development and manufacturing costs are burdensome to health care systems. Biologics being the most expensive prescription drugs on the market limit the accessibility for necessary treatment in t

Совпадение в полном тексте источника
… Oncologist . 2018 ; 23 ( 11 ): 1261 ‐ 1265 . 30049886 10.1634/theoncologist.2018-0066 PMC6291332 11 Congressional Research Service . Biologics and Biosimilars: Background and Key Issues . Updated June 6, 2019. … Biosimilars 101: considerations for US oncologists in clinical practice . Cancer Med . 2014 ; 3 ( 4 ): 889 ‐ 899 . 24810680 10.1002/cam4.258 PMC4303156 27 Kim WS , Ogura M , Kwon H‐C , Choi D . …

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.

Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from chemotherapy and radiation. This review evaluates immune-based therapies and their complications for emergency clinicians. Therapy complications include immune-related adverse events (irAE), cytokine release syndrome (CRS), autoimmune toxicity, and chimeric antigen receptor (CAR) T-cell-related encephalopathy syndrome (CRES). Immune-related adverse

Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective.

ObjectivesThe introduction of innovative, high-cost oncology treatments, coupled with mounting budgetary pressures, necessitates value trade-offs across cancer types. Defining value is critical to informing decision-making. A cost-value analysis tool was used to assess relative clinical value from a US perspective using multiple outcome metrics for a variety of metastatic cancers.MethodsLiterature published (January 1, 2000-August 31, 2016) was reviewed to identify outcome metrics for approved treatments for metastatic cancers. Data were extracted or derived for median and mean overall surviva

Скачок диагноза: доклад по делу о паранеопластической ретинопатии, маскирующейся как синдром белой точки.

Цель этого исследования состояла в том, чтобы сообщить о редком случае предполагаемой паранеопластической ретинопатии у пациента с множественным склерозом, который первоначально представил клинические результаты, указывающие на синдром белых точек. В настоящем докладе описывается сложное нейро-офтальмическое представление, в котором первоначальные диагностические соображения были пересмотрены для достижения окончательного диагноза. 46-летняя женщина с прошлым медицинским прошлым множественным склерозом, с постепенно ухудшающимся зрением в левом глазу, центральным слепым пятном и визуальными на

Early, Patient-Centered, and Multidisciplinary Approach in Newly Diagnosed Multiple Myeloma: What Are We Talking About? A Case Description and Discussion.

Specialized palliative care (SPC) is a multidisciplinary need-based approach from the time a life-threatening disease is diagnosed. Patients with multiple myeloma (MM) will, at the time of diagnosis, often present with symptoms and needs that require a multidisciplinary approach. This case describes the course of a patient with newly diagnosed MM, involving all vertebrae and with no common analgesic treatment providing sufficient relief. High symptom burden and psychosocial and existential factors contribute to his total suffering. SPC, anesthesiological, and radio-oncological disciplines are

Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

CONTEXT: Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ). OBJECTIVE: We aimed to identify the differences various aspects of MRONJ among distinct patient categories and provide recommendations on how to mitigate the risk and optimally manage MRONJ in eac

Euthanasia as a safeguard for living: Anticipation and incurable cancer in a Colombian context.

This article builds on years of ethnographic conversations I sustained with my father, 89, who lives in Colombia. Soon after getting diagnosed with an incurable Multiple Myeloma-a cancer known for unleashing prolonged and painful agonies-he withdrew from oncology treatments and secured access to euthanasia (assisted-dying) on his own, bypassing medico-insurance guidelines created to regulate this medical practice and prevent abuses. Eight years after withdrawing treatments, my dad is still alive. His case shines a light on how securing access to euthanasia may have had unintended therapeutic e

Predictive Modeling for Spinal Metastatic Disease.

Spinal metastasis is exceedingly common in patients with cancer and its prevalence is expected to increase. Surgical management of symptomatic spinal metastasis is indicated for pain relief, preservation or restoration of neurologic function, and mechanical stability. The overall prognosis is a major driver of treatment decisions; however, clinicians' ability to accurately predict survival is limited. In this narrative review, we first discuss the NOMS decision framework used to guide decision making in the treatment of patients with spinal metastasis. Given that decision making hinges on prog

Совпадение в полном тексте источника
… Survival predictions by oncologists, radiation oncologists, and surgeons have been consistently determined to be inaccurate and overly optimistic [ 18 , 19 , 20 , 21 , 22 ]. … Are we better a decade later in the accuracy of survival prediction by palliative radiation oncologists? Ann. Palliat. Med. 2019;8:150–158. doi: 10.21037/apm.2018.11.02. 22. Thio Q.C.B.S., Paulino Pereira N.R., Palthe O.V.W., Sciubba D.M., Bramer J.A.M., Schwab J.H. …

Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study.

BackgroundMany recently approved medications to manage multiple myeloma (MM) are oral, require supportive medications to prevent adverse effects, and are taken under complex schedules. Medication adherence is a concern; however, little attention has been directed toward understanding adherence in MM or associated barriers and facilitators. Advanced sensored medication devices (SMDs) offer opportunities to intervene; however, acceptability among patients with MM, particularly African American patients, is untested.ObjectiveThis study aimed to explore patients' (1) perceptions of their health be

Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience.

IntroductionKhorana score (KS) stratifies patients into low, intermediate, and high risk groups for venous thromboembolism (VTE). We examined the generalizability of the KS to risk of VTE and association with mortality.MethodsA retrospective cohort study was conducted at Mount Auburn Hospital, Cambridge, Massachusetts. Patients aged 18 years or older undergoing chemotherapy were included. All patients were evaluated for a six-month period. Primary study endpoints were VTE or mortality.ResultsSome 277 participants were included with a mean age of 63.95 (standard deviation, SD ± 12.47). The inci

Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study.

PURPOSE: Bisphosphonates and non-bisphosphonate antiangiogenic and antiresorptive agents are widely used in the management of bone diseases and cancer. A subset of patients receiving these drugs can manifest with medication-related osteonecrosis of the jaw (MRONJ) and it is one of the major complications faced in dental practice. Dentoalveolar and periodontal surgery are the major risk factors associated with it. Therefore, a dentist must have adequate knowledge to promptly identify patients at risk and efficiently manage the condition. This multicentre study was designed with an aim to assess

Совпадение в полном тексте источника
… Dentists should also promptly identify this group of patients as risk-prone and manage efficiently. 4 There have been few studies about BRONJ awareness among medical professionals, oncologist and dentists in different regions but to the best of our knowledge only one study has assessed the awareness … Oncologists awareness about bisphosphonate related osteonecrosis of the jaws. J PakMed Assoc. 2016;66:880–883. Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. …

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.

Both overall survival (OS) and progression-free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, the impact of oncology drug prices on OS and PFS is unclear. We analyzed the relationship between oncology drug prices and clinical outcomes in Japan. The costs of a full course or 1 year of treatment were estimated on the basis of the latest National Health Insurance Drug Price Standards, and the relationship between costs and improvements in OS or PFS obtained with each d

Совпадение в полном тексте источника
… Since the launch of the ICI nivolumab on the Japanese market, the extremely high price of this drug created a debate on the cost‐effectiveness of oncology drugs among patients, oncologists, and the media in Japan. … In general, oncologists prescribe anticancer drugs until disease progression, and PFS and OS have been prolonged. …

EVALUATION OF QUALITY OF LIFE IN PATIENTS TREATED FOR METASTATIC DISEASE OF THE PROXIMAL FEMUR.

OBJECTIVE: Patients with metastatic bone lesions have a limited life expectancy. These metastatic lesions compromise the proximal femur, and fractures are quite common. The survival of these patients depends on the behavior of the primary tumor. The aim of this study was to evaluate the quality of life of patients with extensive metastatic lesion of the proximal femur with pathological or imminent fracture, treated with non-conventional endoprosthesis. METHODS: From May 2008 to August 2012, twenty-five (25) patients with bone metastases of the proximal femur, with pathological or imminent fra

Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies.

Background and aimsImmunotherapies for cancers are tested in large numbers of clinical trials. It is difficult for clinicians and researchers to stay current with the evidence, and traditional systematic reviews and clinical guidelines are not suited to ensure a continued overview of all trials and their results. To address this problem, we designed the Cancer Immunotherapy Evidence Living (CIEL) Library.MethodsWe included planned, ongoing, and completed interventional trials of immunotherapies for cancer, regardless of trial design (e.g., randomization, blinding, and type of comparator). We s

An Innovative Patient Stratification Tool Integrating Clinical and Economic Data for Benchmarking Oncology and Hematology Care: The PATONCOS System.

Background: The growing complexity and cost of oncohematological treatments has created an urgent need for standardized methodologies capable of enabling inter-institutional comparisons of healthcare expenditure within homogeneous patient groups. Cancer-related pharmaceutical costs vary substantially depending on tumour type, disease stage, and therapeutic approach, making cross-institutional benchmarking challenging due to heterogeneity in patient populations and clinical practice patterns. Therefore, integrating cost analysis with clinically meaningful patient stratification is essential to

Совпадение в полном тексте источника
… The classification system was validated through multidisciplinary collaboration with oncologists and hematologists. Figure 1 Conceptual framework of the PATONCOS tool. … A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs ESMO Open 2024 9 103976 10.1016/j.esmoop.2024.103976 39510022 PMC11575190 8. Bhimani J. Philipps L. Simpson L. Lythgoe M. Soultati A. Webb A. Savage P. …

Functional and Rehabilitative Outcomes of Patients Affected by Bone Cancer of the Upper Limb Treated with MUTARS Prosthesis: A Narrative Review.

Megaprostheses are well-known, reliable, and effective reconstruction prostheses used in oncologic surgery for limb salvage in patients affected by primary or metastatic bone tumors. Rehabilitation plays a major role after MUTARS replacement, with the aim of improving function after surgery and maintaining the highest possible quality of life. Only a few studies have been published about the use of megaprostheses for the upper limb. The aim of this narrative review is to describe the results of functional and rehabilitative outcomes of patients affected by bone primary or metastatic bone cance

Совпадение в полном тексте источника
… Therefore, the complexity of care necessitates systematic multidisciplinary team management and should be performed in reference centers capable of providing access to the full spectrum of care, beginning with the diagnosis, involving oncologists, radiologists, and histopathologists, and then the treatment … where not only the orthopedic surgeons play a main role, but also radiotherapists, psycho-oncologists, and oncologists. …

Коэффициенты вакцинации от пневмонии и гриппа у онкологических пациентов - данные из Германии.

ЦЕЛИ: Из-за иммунодепрессии, связанной с болезнями или терапией, онкологические пациенты страдают значительно более высокой заболеваемостью и смертностью в результате инфекций, передаваемых такими респираторными патогенами, как пневмония Стрептококка и вирус гриппа. Хотя Постоянный комитет Германии по вакцинации (НТИКО) выносит конкретные рекомендации в отношении вакцинации от этих патогенов, данные о коэффициентах вакцинации этой группы населения, подверженной высокому риску, отсутствуют. МЕТОДЫ: Для получения информации о показателях вакцинации от пневмонии стрептокококка и вируса гриппа у о

Совпадение в полном тексте источника
… A recent Italian survey showed similar limitations regarding knowledge, awareness, and attitude in oncologists [ 5 ]. … On the other hand, vaccination schedules are typically not perceived as one of the tasks of oncologists; therefore, they mostly do not check and provide vaccinations for their patients [ 6 ]. …

Generic Health Utility Measures in Exercise Oncology: A Scoping Review and Future Directions.

Despite the evidence that exercise is effective at mitigating common side effects in adults with cancer, it is rarely part of usual cancer care. One reason for this is the lack of economic evidence supporting the benefit of exercise. Economic evaluations often rely on the use of generic utility measures to assess cost effectiveness. This review identifies and synthesizes the literature on the use of generic utility measures used to evaluate exercise interventions for adults with cancer. A systematic search of the literature from January 2000 to February 2023 was conducted using four databases

Совпадение в полном тексте источника
… Effective Physical Activity Promotion to Survivors of Cancer Is Likely to Be Home Based and to Require Oncologist Participation J. Clin. Oncol. 2017 35 3635 3637 10.1200/JCO.2017.74.6032 28915086 49. Hardcastle S.J. Cohen P.A. Reply to S.C. Adams et al., C. Lopez et al., and R.U. Newton et al J. … Effective Exercise Interventions for Patients and Survivors of Cancer Should be Supervised, Targeted, and Prescribed With Referrals From Oncologists and General Physicians J. Clin. Oncol. 2018 36 927 928 10.1200/JCO.2017.76.7400 29373097 51. An K.Y. Arthuso F.Z. Kang D.W. Morielli A.R. …

Elements for assistance to patients with hematological malignancies to propose care lines: a scoping review.

Objectivesto identify the elements for assistance to patients with hematological malignancies to propose a care line.Methodsthis is a scoping review, anchored in the JBI theoretical framework, with searches carried out in April 2021, in eight electronic databases and 10 repositories of theses and dissertations.Resultsthe final sample consisted of 93 studies, and the main forms of assistance provided that can support a care line for this public were imaging tests, immunophenotyping, chemotherapy regimens, radiotherapy, infection management, assessment of nutritional status, maintenance of oral